i didn't expect it to test mid 2s until early June.
Tax loss season could be crushing for IMU given that >20k shareholders were in the red at the time of the last annual report... the SP has almost halved since then.
If shareholders truly believe that CF33 could be revolutionary to oncology, they should really be ashamed with themselves for allowing IMU to run this opportunity into the ground.
IMU Price at posting:
2.6¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)